A new vaccine developed by Pfizer and the German biotechnology firm BioNTech was more than 90% effective at protecting people from COVID-19.
The ORCHID trial was halted in June 2020 after it was determined that hydroxychloroquine was unlikely to benefit hospitalized patients.
A phase 3 trial evaluating the vaccine candidate mRNA-1273 against COVID-19 met its primary efficacy end point in the first interim analysis.
Study authors assessed the incidence, time-trends, and outcomes of serious infections in Sjögren syndrome.
Study authors assessed whether azithromycin in addition to a hydroxychloroquine regimen shows positive results in clinical improvement or mortality reduction in patients hospitalized with severe COVID-19.
The global burden of musculoskeletal disorders is considerable, but prevalence and DALYs have decreased slightly since 1990.
The COVID-19 Global Rheumatology Alliance Patient Experience Survey was used to assess the effect of antimalarial drug shortages during the COVID-19 pandemic.
Neurologic disturbances in patients with coronavirus disease 2019 were accompanied by evidence of cytokine release syndrome.
In the event of a likely scarcity of COVID-19 vaccines, a framework must be developed to inform who should get priority.
Clinicians should use caution when interpreting the guidelines for the diagnosis and detection of sarcoidosis and must consider unique individual clinical circumstances when managing these patients.
For patients with moderate COVID-19, convalescent plasma does not reduce progression to severe COVID-19 or mortality.
Tocilizumab may be beneficial for adults with COVID-19 admitted to the ICU although other findings are conflicting.
Vertebral fractures (VFs) are a clinical marker of fragility and poor prognosis in patients with COVID-19.
Hospitalized patients with COVID-19 more often have a vitamin D deficiency than population-based controls.
Cytokine levels in severely, critically ill COVID-19 patients are much lower than in other inflammatory syndromes.